Phathom Pharmaceuticals, Inc. (PHAT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Phathom Pharmaceuticals, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 7.85 at 5:30 am ET, low 7.49 at 3:45 pm ET.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
the bull case· 3
4
disclosed supplier and customer ties in SEC filings
sec filingsedgar3
of the funds on file reporting a position in PHAT
n-portas of Jun 30 '26+4.00%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 3
5 of 7
recent reports where the move came in under the options implied range
earnings historyimplied vs realized7 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2621
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 5 '26 report. Not a forecast, not advice.
Of the 5 companies Phathom Pharmaceuticals, Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
162 managers report a position worth $793.4M between them, and 21 of them hold 80% of it.
tall tick = annual report · 1 on record
PHAT (Phathom Pharmaceuticals, Inc.) has 4 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.